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reported among the elderly (74.21%), significant variations across age groups, re-
gions, and insurance types observed in this well-insured group call for future re-
search to better understand reasons behind these variations.
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OBJECTIVES: In Japan, the screening rates for breast and cervical cancers have been
lower than in other countries, with rates below 20%. Breast cancer screening has
been conducted biennially for over 40 years, and cervical cancer screening has been
conducted biennially for over 20 years. Since lack of resources is an important
barrier to increasing cancer screening rates, relationships between resources and
cancer screening rates were investigated for breast and cervical cancers in Japan.
METHODS: Based on the national data from 2008, the resource gap among 47
prefectures was compared. Resources were defined by the number of mammogra-
phy equipment installations (per 100,000 women) for breast cancer screening and
the number of gynecologists (per 100,000 women) for cervical cancer screening.
Correlations between the screening rates and the availability of resources were
calculated. RESULTS: The national average breast cancer screening rate was 14.7%,
varying from 2.5% to 35% among the 47 prefectures. The national average number
of mammography equipment installations was 5.88 per 100,000, ranging from 8.81
to 4.41 per 100,000 among the 47 prefectures. The correlation between mammog-
raphy equipment installations and the screening rate for breast cancer was 0.420
(P0.01). The national average cervical cancer screening rate was 19.4%, varying
from 12.1% to 34.8% among the 47 prefectures. The national average number of
gynecologists was 18.0 per 100,000, ranging from 13.1 to 25.9 per 100,000 among the
47 prefectures. The correlation between the number of gynecologists and the cer-
vical cancer screening rate was -0.079 (n.s). CONCLUSIONS: Although the breast
cancer screening rate shows a close relationshipwithmedical resource availability,
there is no relationship for cervical cancer screening. Since medical resources to
increase breast cancer screening are limited in local areas, sufficient resources
should be provided. In cervical cancer screening, other factors that affect the
screening rate should be investigated.
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OBJECTIVES: Non-participation by potential study subjects in population research
can affect the validity and generalizability of study outcomes. The study objectives
were to evaluate the differences between participants and non-participants who
were targeted for enrollment in the Bonnie’s Bus Mobile Mammography Program
(BBMMP) conducted throughout West Virginia, and to determine the predictors of
willingness to participate in future research among those who consented to pro-
vide initial surveillance data. METHODS: Data collected from 2441 women who
were screened in the BBMMP were analyzed using the chi-square test and logistic
regression. RESULTS: Of the 2441 women who were screened by BBMMP over a 3
year period, 1178 women (48.3%) chose not to consent to participate in the surveil-
lance study. Bivariate analysis indicated that being over 65 years, single, over-
weight, uninsured, unemployed, or of minority race were associated with non-
enrollment in the study. The multivariate adjusted model indicated that being of
age 65 years and above (AOR2.10), being single (AOR1.25), or being from a mi-
nority race (AOR1.97) were significant predictors of non-participation. Of the
1,263 women who consented to participate in the study and provided surveillance
data, 407 women (32.2%) declined to being contacted for participation in future
breast cancer screening research. The unadjustedmodel showed that womenwho
have breast problems, are adherent to mammography screening guidelines, and
aremarried/partnered aremore likely to bewilling to participate in future research.
Multivariate logistic regression analysis revealed that women adherent to mam-
mography screening guidelines are more likely to agree (AOR1.40) to participate
in future research than non adherent women. CONCLUSIONS:Women who are at
risk for breast cancer and who are likely targets for interventions to increase ad-
herence to mammography screening guidelines are more likely to not participate
in breast cancer screening studies than those who may not be at risk and are
adherent to screening guidelines.
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OBJECTIVES: Few studies have focused on access to care for women through utili-
zation of a mobile mammography unit. Bonnie’s Bus Mammography Mobile Pro-
gram (BBMMP) was created to provide mammograms to women in rural areas
throughout West Virginia (WV) and surrounding areas. Based on a 3-year analysis
of the data, 80.4% of its clientele had a BMI of 30 or above as compared to 64.9% for
all WV women age 40 and above. Thus, the objectives of the study were to: 1) to
describe the demographics and comorbidities of womenwho utilized BBMP, and 2)
to determine the association between BMI and personal health and screening his-
tory, preventive care, and wellness behaviors. METHODS: Three years BBMP sur-
veillance data collected from 1099 women age 40 and above were analyzed. BMI by
personal health and screening history, preventive care, wellness behaviors, and
demographics were analyzed using descriptive statistics, chi-square tests, and a
linear regression model. RESULTS: Women were mostly married (60.4%), had
health insurance (53.2%), were employed (46.5%), and had an annual income be-
tween $10,000-25,000 (40.9%). Major comorbidities were hypertension (49%) and
high cholesterol (43.9%). Increasing BMI was associated with greater likelihood of
thyroid disease, hypertension, diabetes, high cholesterol, allergies, hormone re-
placement therapy use, activity limitations, perceived weight problem, lower ex-
ercise, inability to getmedications due to cost, lower doctor visits, and being single.
Those with lower BMI were less likely to smoke or drink alcohol. The regression
model was significant (F13.729, p0.001, R2  0.412) and indicated that women
who engaged in preventive care behaviors were less likely to be obese than those
who did not. CONCLUSIONS: The BBMMP attracted women who were dispropor-
tionately obese and had multiple co-morbidities, thus providing a great opportu-
nity for targeted interventions related to improving preventive care, screening, and
self-care behaviors.
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OBJECTIVES: Specialty pharmacy programs are increasingly used to improve the
quality of outpatient therapy with oral medications for cancer. We evaluated
whether use of particular specialty pharmacy services is associated with improved
oncology medication use and reduced overall healthcare costs, as compared to
retail pharmacy services. METHODS: The study is a retrospective claims analysis
post implementation of a specialty pharmacy program, by a national commercial
payer. A matched sample of patients assigned to use specialty pharmacies and
those who used retail pharmacies for oral cancer therapies were compared. Pri-
mary outcomes were financial, including overall health care costs, outpatient
costs, medical costs, and pharmacy costs. Outcomes one year post-implementa-
tion in specialty pharmacy users and retail pharmacy controlswere comparedwith
t-tests for continuous variables, chi-square for nominal variables, and logistic re-
gression for matching. Propensity scores were used to adjust for unmeasured con-
founding in the groups. RESULTS: The final analysis included 464 patients per
cohort. The mean total costs per patient was 13% lower in the specialty pharmacy
group ($84,105 vs. $97,196; difference  $-13,092; P  0.02) in the follow-up period.
The mean outpatient hospital costs ($16,777 vs. $28,629, difference  $-11,852; P 
0.01) were lower in the specialty group by 41%, with an associated significant dif-
ference in outpatient hospital visits (15.75 vs. 19.66, P  0.01). Patients in the spe-
cialty pharmacy groupweremore adherent to therapy, MPR 0.73 vs. 0.66, (P 0.01).
CONCLUSIONS: This specialty pharmacy program implemented by a national
commercial payer appears to improve oral oncology medication adherence and
decrease overall health care costs, mainly by impacting outpatient hospital utili-
zation.
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OBJECTIVES: The rising costs of cancer care have caused concerns regarding the
increasingOOP burden on cancer patients. The objective of this study is to examine
patients’ OOP expenditures on G-CSF, pegfilgrastim and filgrastim, two supportive-
care agents for cancer patients treated with myelosuppressive chemotherapy.
METHODS: Two large US health care claims databases (2008-Q2 2010 MarketScan®
Commercial and Medicare Supplemental Databases, and 2007-Q2 2009 HealthCore
Integrated Research DatabaseSM) were used to identify adult patients receiving
chemotherapy and G-CSF in outpatient settings. The summary statistics of quar-
terly OOP costs were tabulated for patients with any G-CSF claim for each quarter
during Q1 2007-Q2 2010. Costs were adjusted to June 2010 dollars. RESULTS: The
pattern of patients’ OOP costs for G-CSF was generally consistent between the two
data sources and over time. On average, about 65-75% of patients on G-CSF in-
curred zero OOP costs in a quarter. Across the years, the average quarterly OOP
costs per patient for all patients ranged from $100-$150 for pegfilgrastim and $50-
$100 for filgrastim.When focusing on the 20,948 patients onG-CSFwith continuous
health plan enrollment throughout 2009 in MarketScan®, mean OOP costs/patient/
quarter were $100 for pegfilgrastim and $53 for filgrastim. On average 69.2% of
pegfilgrastim patients and 63.9% of filgrastim patients had zero OOP costs in a
quarter. Very few patients (5.5% of pegfilgrastim and 2.7% of filgrastim) had quar-
terly OOP costs reaching $500 or above. The subgroup of patients with $0 quar-
terly OOP costs had mean costs/patient/quarter that were $324 for pegfilgrastim
and $146 for filgrastim. During 2009, that subgroup had an average of 2.4 adminis-
trations and/or prescriptions per quarter for pegfilgrastim and 5.5 for filgrastim.
The mean OOP costs of those administrations and/or prescriptions were $128 for
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